NEW YORK (GenomeWeb) – Celsee said today that it has entered a co-commercialization agreement with IncellDx for several products, including a 20-marker lung cancer genomics and proteomics panel, a CTC-based screening test for breast, colorectal, prostate, and other cancers, and a cell-based NIPT assay.
The companies said that their announcement follows the successful completion of a feasibility study that analyzed PD-L1 expression in lung cancer biopsy and blood specimens using the IncellDx OncoTect iO Single Cell Quantitative PD-L1 assay and the Celsee C-Prep Genesis platform.
In the study, which was presented last year at the annual meeting of the Association for Molecular Pathology, several patient samples showed a positive expression for PD-L1 in CTCs using the companies' combined technologies, but showed only minimal expression using standard-of- care methods.
"The coupled ability of IncellDx's technology to generate single cell suspensions with Celsee's technology to isolate and analyze single cells derived from peripheral blood and tissue will create a new standard for clinical research and for future diagnostic applications," Celsee CEO John Stark said in a statement.
Financial terms of the agreement were not disclosed.